CSF2 and COVID-19: Immunomodulatory therapies, including interleukin inhibitors targeting IL-1 and IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), and Janus Kinase (JAK) inhibitors, are designed to reduce the cytokine dysregulation seen in severe COVID-19, though their impact on the disease’s thrombotic complications remain poorly understood (2).